Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
4,129 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01746225 | Schedules of Nab-Paclitaxel in Metastatic Breast Cancer(SNAP) | completed | Phase 2 | 258 | ETOP IBCSG Partners FoundationNETWORK | 6 | Sep 2, 2026 | clinicaltrials |
| NCT03394365 | A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy(ALLELE) | recruiting | Phase 3 | 115 | Pierre Fabre MedicamentINDUSTRY |
| 9 |
| Sep 2, 2026 |
| clinicaltrials |
| NCT05862285 | A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study(UmbrellaMAX) | recruiting | Phase 3 | 100 | Hoffmann-La RocheINDUSTRY | 15 | Sep 2, 2026 | clinicaltrials |
| NCT06652438 | Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML | recruiting | Phase 3 | 448 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 18 | Sep 2, 2026 | clinicaltrials |
| NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer(ACTIVATED-4-PC) | recruiting | Phase 1 / Phase 2 | 52 | AstraZenecaINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT00553410 | Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer(SOLE) | completed | Phase 3 | 4,884 | ETOP IBCSG Partners FoundationNETWORK | 20 | Sep 1, 2026 | clinicaltrials |
| NCT04619004 | HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 277 | Daiichi SankyoINDUSTRY | 16 | Sep 1, 2026 | clinicaltrials |
| NCT05508867 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) | completed | Phase 2 | 203 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Sep 1, 2026 | clinicaltrials |
| NCT07223814 | Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) | recruiting | Phase 3 | 875 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 12 | Sep 1, 2026 | clinicaltrials |
| NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer(OC) | recruiting | Phase 1 / Phase 2 | 72 | Tubulis GmbHINDUSTRY | 3 | Sep 1, 2026 | clinicaltrials |
| NCT03977753 | Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts(EVAsION) | recruiting | Phase 4 | 162 | Labo'LifeINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04308278 | Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection(EBVAST) | recruiting | Phase 4 | 88 | Labo'LifeINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT04538664 | A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions(PAPILLON) | active not recruiting | Phase 3 | 308 | Janssen Research & Development, LLCINDUSTRY | 26 | Aug 31, 2026 | clinicaltrials |
| NCT00781612 | A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies | active not recruiting | Phase 2 | 378 | Genentech, Inc.INDUSTRY | 35 | Aug 28, 2026 | clinicaltrials |
| NCT03473743 | A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer | active not recruiting | Phase 1 / Phase 2 | 125 | Janssen Research & Development, LLCINDUSTRY | 13 | Aug 28, 2026 | clinicaltrials |
| NCT04449874 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | active not recruiting | Phase 1 | 498 | Genentech, Inc.INDUSTRY | 17 | Aug 28, 2026 | clinicaltrials |
| NCT04486378 | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | active not recruiting | Phase 2 | 327 | BioNTech SEINDUSTRY | 7 | Aug 28, 2026 | clinicaltrials |
| NCT04802590 | Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | active not recruiting | Phase 2 | 210 | The Lymphoma Academic Research OrganisationOTHER | 3 | Aug 28, 2026 | clinicaltrials |
| NCT04971226 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | active not recruiting | Phase 3 | 405 | Novartis PharmaceuticalsINDUSTRY | 29 | Aug 28, 2026 | clinicaltrials |
| NCT05211895 | A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC(PACIFIC-8) | active not recruiting | Phase 3 | 791 | AstraZenecaINDUSTRY | 28 | Aug 28, 2026 | clinicaltrials |
| NCT06132958 | Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)(TroFuse-005) | active not recruiting | Phase 3 | 710 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Aug 28, 2026 | clinicaltrials |
| NCT06459180 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | active not recruiting | Phase 3 | 686 | Merck Sharp & Dohme LLCINDUSTRY | 32 | Aug 28, 2026 | clinicaltrials |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | active not recruiting | Phase 4 | 163 | Novartis PharmaceuticalsINDUSTRY | 19 | Aug 27, 2026 | clinicaltrials |
| NCT04077723 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 498 | Hoffmann-La RocheINDUSTRY | 12 | Aug 27, 2026 | clinicaltrials |
| NCT05338970 | HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy | active not recruiting | Phase 3 | 586 | Daiichi SankyoINDUSTRY | 21 | Aug 27, 2026 | clinicaltrials |
| NCT06158841 | Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma(CERVINO) | active not recruiting | Phase 3 | 421 | AbbVieINDUSTRY | 25 | Aug 27, 2026 | clinicaltrials |
| NCT01652469 | Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.(EMPHASIS) | completed | Phase 3 | 81 | ETOP IBCSG Partners FoundationNETWORK | 12 | Aug 26, 2026 | clinicaltrials |
| NCT02477696 | Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 3 | 533 | Acerta Pharma BVINDUSTRY | 15 | Aug 26, 2026 | clinicaltrials |
| NCT02536742 | Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer(PYTHIA) | completed | Phase 2 | 124 | ETOP IBCSG Partners FoundationNETWORK | 3 | Aug 26, 2026 | clinicaltrials |
| NCT03448042 | A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers | active not recruiting | Phase 1 | 123 | Genentech, Inc.INDUSTRY | 13 | Aug 26, 2026 | clinicaltrials |
| NCT03644186 | To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)(TOUCH) | completed | Phase 2 | 147 | ETOP IBCSG Partners FoundationNETWORK | 4 | Aug 26, 2026 | clinicaltrials |
| NCT04025879 | A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 461 | Bristol-Myers SquibbINDUSTRY | 22 | Aug 26, 2026 | clinicaltrials |
| NCT04214288 | A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer(SERENA-2) | active not recruiting | Phase 2 | 240 | AstraZenecaINDUSTRY | 16 | Aug 26, 2026 | clinicaltrials |
| NCT04656652 | Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) | active not recruiting | Phase 3 | 605 | Daiichi SankyoINDUSTRY | 26 | Aug 26, 2026 | clinicaltrials |
| NCT05328908 | A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer(RELATIVITY-123) | terminated | Phase 3 | 769 | Bristol-Myers SquibbINDUSTRY | 22 | Aug 26, 2026 | clinicaltrials |
| NCT05625399 | A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma(RELATIVITY-127) | active not recruiting | Phase 3 | 579 | Bristol-Myers SquibbINDUSTRY | 19 | Aug 26, 2026 | clinicaltrials |
| NCT07128199 | A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection(REZILIENT4) | active not recruiting | Phase 3 | 360 | Taiho Oncology, Inc.INDUSTRY | 24 | Aug 26, 2026 | clinicaltrials |
| NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer(RAINFOL-05) | recruiting | Phase 2 | 240 | GenmabINDUSTRY | 13 | Aug 26, 2026 | clinicaltrials |
| NCT02475681 | Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL(ElevateTN) | active not recruiting | Phase 3 | 535 | Acerta Pharma BVINDUSTRY | 18 | Aug 25, 2026 | clinicaltrials |
| NCT02568267 | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)(STARTRK-2) | active not recruiting | Phase 2 | 534 | Hoffmann-La RocheINDUSTRY | 16 | Aug 25, 2026 | clinicaltrials |
| NCT04039607 | A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma(CheckMate 9DW) | completed | Phase 3 | 732 | Bristol-Myers SquibbINDUSTRY | 26 | Aug 25, 2026 | clinicaltrials |
| NCT04770896 | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab(IMbrave251) | active not recruiting | Phase 3 | 557 | Hoffmann-La RocheINDUSTRY | 28 | Aug 25, 2026 | clinicaltrials |
| NCT05487248 | A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients(COPERNIC) | completed | N/A | 103 | Jules Bordet InstituteOTHER | 2 | Aug 25, 2026 | clinicaltrials |
| NCT06276491 | Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | recruiting | Phase 1 | 282 | Xencor, Inc.INDUSTRY | 4 | Aug 25, 2026 | clinicaltrials |
| NCT06797362 | Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors | available | — | — | Nuvalent Inc.INDUSTRY | 10 | Aug 25, 2026 | clinicaltrials |
| NCT02046733 | Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease(STIMULI) | completed | Phase 2 | 222 | ETOP IBCSG Partners FoundationNETWORK | 8 | Aug 24, 2026 | clinicaltrials |
| NCT02434081 | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma(NICOLAS) | completed | Phase 2 | 94 | ETOP IBCSG Partners FoundationNETWORK | 5 | Aug 24, 2026 | clinicaltrials |
| NCT05020236 | A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments(MAGNETISMM-5) | recruiting | Phase 3 | 893 | PfizerINDUSTRY | 26 | Aug 24, 2026 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials